- Project 3 Metastatic progression of prostate cancer to the bone is not curable. Interestingly, the detailed study of paired prostatic tissues from treatment-nave patients who present with bone metastatic disease at diagnosis revealed that the prostatic epithelia of the primary tissue express proteins that are commonly found in cells that reside in the vascular sinusoids and endostea of the bone marrow. More specifically, the primary tumor cells of patients with bone metastasis seemed to mimic megakaryocytes and osteoblasts - to be termed MO-mimicry. We further found that transgenic mice with a loss of TGF-beta receptor type II expression in the prostatic fibroblasts support the MO-mimicry phenotype and can support the expansion of adjacent epithelia in the bone microenvironment. The microdissection of stromal cells around the cancer epithelia expressing MO-mimicry features revealed the juxtacrine signaling pathways involving Notch signaling and associated transcription factors that were epigenetically up regulated. Thus, by stromal-epithelial interactions in the primary prostate tumor mimicking bone marrow cells it may enable the tumor cells to survive in the bone niche. If true, this suggests that primary tumor foci may hold the risk determinants for bone colonization. It would be a leap in clinical diagnosis capability if prostate biopsy tissue could diagnose or predict the otherwise undetectable bone metastatic disease. In this highly collaborative proposal we hope to provide the biologic and clinical evidence to address the hypothesis, primary tumor microenvironment facilitates epithelial acquisition of MO-mimicry features that enable colonization of bone.
In Aim 1 we will define the role of carcinoma associated fibroblasts in inducing and/or supporting MO-mimicry. These studies will involve the interrogation of the heterogeneous fibroblasts that support Notch-signaling mediated expansion of PC epithelia in bone.
In Aim 2 we will evaluate interactions of MO-mimicry PC epithelia at the vascular and endosteal niche on bone engraftment. We will determine if blocking the marrow vascular niche where megakaryocytes reside affect bone dissemination and endosteal colonization. Finally, in Aim 3 we will determine if detection of the MO-mimicry profile in diagnostic prostate biopsies is an indicator of clinical bone metastases and/or occult bone metastasis.

Public Health Relevance

- Project 3 The question of whether specific metastasis-initiating cells exist within treatment-nave prostate cancers versus if all tumor cells have the potential to adapt to the bone microenvironment remains unanswered. In order to elucidate traits of primary prostate tumors that support skeletal dissemination and colonization, it is critical to evaluate epithelia and stroma interactions in the setting of concurrent bone metastases. This approach will delineate microenvironmental factors that influence the development and expansion of metastatic precursors within the prostate, as well as identify key pathways required for interaction at the bone niche.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Cedars-Sinai Medical Center
Los Angeles
United States
Zip Code
Rohena-Rivera, Krizia; Bhowmick, Neil A (2018) Notch inhibitor screening reveals an unexpected HES1 heterodimer. J Biol Chem 293:8295-8296
Tighiouart, Mourad; Cook-Wiens, Galen; Rogatko, André (2018) A Bayesian adaptive design for cancer phase I trials using a flexible range of doses. J Biopharm Stat 28:562-574
Madhav, Anisha; Andres, Allen; Duong, Frank et al. (2018) Antagonizing CD105 enhances radiation sensitivity in prostate cancer. Oncogene 37:4385-4397
Jan, Yu Jen; Chen, Jie-Fu; Zhu, Yazhen et al. (2018) NanoVelcro rare-cell assays for detection and characterization of circulating tumor cells. Adv Drug Deliv Rev 125:78-93
Grindel, Brian J; Martinez, Jerahme R; Tellman, Tristen V et al. (2018) Matrilysin/MMP-7 Cleavage of Perlecan/HSPG2 Complexed with Semaphorin 3A Supports FAK-Mediated Stromal Invasion by Prostate Cancer Cells. Sci Rep 8:7262
Jimenez, Jose L; Tighiouart, Mourad; Gasparini, Mauro (2018) Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents. Biom J :
Martinez, Jerahme R; Grindel, Brian J; Hubka, Kelsea M et al. (2018) Perlecan/HSPG2: Signaling role of domain IV in chondrocyte clustering with implications for Schwartz-Jampel Syndrome. J Cell Biochem :
Conley, Andrew; Minciacchi, Valentina R; Lee, Dhong Hyun et al. (2017) High-throughput sequencing of two populations of extracellular vesicles provides an mRNA signature that can be detected in the circulation of breast cancer patients. RNA Biol 14:305-316
Farach-Carson, Mary C; Lin, Sue-Hwa; Nalty, Theresa et al. (2017) Sex Differences and Bone Metastases of Breast, Lung, and Prostate Cancers: Do Bone Homing Cancers Favor Feminized Bone Marrow? Front Oncol 7:163
Stewart, Paul A; Khamis, Zahraa I; Zhau, Haiyen E et al. (2017) Upregulation of minichromosome maintenance complex component 3 during epithelial-to-mesenchymal transition in human prostate cancer. Oncotarget 8:39209-39217

Showing the most recent 10 out of 215 publications